Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05502523 · ClinicalTrials.gov registry record · NA
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
A NA study of Lung Non-Small Cell Carcinoma and Stage III Lung Cancer AJCC v8, sponsored by Thomas Jefferson University.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 4
- Study locations
NCT05502523 is a NA study of Lung Non-Small Cell Carcinoma and Stage III Lung Cancer AJCC v8 that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 100 participants, below the 158-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (37% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT05502523, a NA study of Lung Non-Small Cell Carcinoma and Stage III Lung Cancer AJCC v8, is actively recruiting participants, sponsored by Thomas Jefferson University.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Pulmonary Artery-First Surgical Technique
Study Locations (4)
Pennsylvania
- Abington Memorial Hospital - Abington
- Jefferson Health Northeast - Philadelphia
- Thomas Jefferson University Hospital - Philadelphia
- Asplundh Cancer Pavilion at Jefferson Health - Willow Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2029-01-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05502523
The ClinicalTrials.gov registry entry for NCT05502523 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 158-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (37% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT05502523 reports 4 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05502523 about?
NCT05502523 is a clinical study titled "The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer". This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first ...
What is the current status of trial NCT05502523?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-08-31. Estimated completion is 2029-01-01.
What conditions does trial NCT05502523 study?
This clinical trial studies the following conditions: Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8.
What interventions are being tested in trial NCT05502523?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Pulmonary Artery-First Surgical Technique (PROCEDURE).
Who is sponsoring clinical trial NCT05502523?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05502523 being conducted?
This trial has 4 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Non-Small Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
RECRUITING · NA
-
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
RECRUITING · NA
-
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
RECRUITING · NA
-
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
RECRUITING · NA
-
Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
RECRUITING · NA
-
Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
RECRUITING · NA
Explore more on PlainTrial
Lung Non-Small Cell Carcinoma
All registered trials for this condition
Stage III Lung Cancer AJCC v8
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.